Trillium Therapeutics (TSE:TRIL) Stock Price, News, Analysis & History

C$9.81 +0.06 (+0.62 %)
(As of 03/23/2018 05:19 AM ET)
Previous CloseC$9.75
Today's RangeC$8.91 - C$9.90
52-Week RangeC$5.26 - C$16.80
Volume4,983 shs
Average Volume7,552 shs
Market CapitalizationC$124.24 million
P/E Ratio-1.92
Dividend YieldN/A

About Trillium Therapeutics (TSE:TRIL)

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-1.92307692307692
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSC($5.07)
Net IncomeN/A
Net MarginsN/A
Return on Equity-259.65%
Return on Assets-55.25%


Outstanding Shares13,147,000

Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

Who are some of Trillium Therapeutics' key competitors?

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the folowing people:

  • Calvin R. Stiller M.D., Independent Chairman of the Board
  • Niclas Stiernholm, President, Chief Executive Officer, Director
  • James T. Parsons, Chief Financial Officer
  • Malik Slassi, Senior Vice President - Discovery Research
  • Robert Uger, Chief Scientific Officer
  • Scott Duncan, Director of Intellectual Property
  • Penka Petrova, Chief Development Officer
  • Eric L Sievers, Chief Medical Officer
  • Luke M. Beshar CPA, Independent Director (Age 59)
  • Henry Friesen M.D., Independent Director (Age 79)

Has Trillium Therapeutics been receiving favorable news coverage?

News stories about TRIL stock have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trillium Therapeutics earned a coverage optimism score of 0.24 on Accern's scale. They also gave news coverage about the company an impact score of 47.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately C$9.81.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of C$124.24 million.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.

MarketBeat Community Rating for Trillium Therapeutics (TRIL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trillium Therapeutics (TSE:TRIL) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Earnings History for Trillium Therapeutics (TSE:TRIL)

No earnings announcements for this company have been tracked by


Trillium Therapeutics (TSE:TRIL) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Trillium Therapeutics (TSE:TRIL)

No dividend announcements for this company have been tracked by

Insider Trades

Trillium Therapeutics (TSE TRIL) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Trillium Therapeutics (TSE:TRIL)

Trillium Therapeutics (TSE TRIL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2017Gordon Edward ZelkoDirectorBuy93,000C$0.11C$10,230.00
6/30/2017Michael Bruno John Fr EnglandDirectorBuy54,000C$0.11C$5,940.00
6/15/2017John Parker MastersDirectorBuy50,000C$0.12C$6,000.00
6/6/2017Michael Bruno John Fr EnglandDirectorBuy19,000C$0.11C$2,090.00
5/2/2017Michael Bruno John Fr EnglandDirectorBuy100,000C$0.15C$15,000.00
4/20/2017Michael Bruno John Fr EnglandDirectorBuy11,500C$0.12C$1,380.00
4/19/2017Michael Bruno John Fr EnglandDirectorBuy50,000C$0.12C$6,000.00
4/13/2017Donald Laughlin MckinnonDirectorBuy20,000C$0.13C$2,600.00
4/10/2017Michael Bruno John Fr EnglandDirectorBuy12,000C$0.10C$1,200.00
3/27/2017Michael Bruno John Fr EnglandDirectorBuy5,000C$0.19C$950.00
3/22/2017Gordon Edward ZelkoDirectorBuy20,000C$0.10C$2,000.00
2/17/2017Michael Bruno John Fr EnglandDirectorBuy50,000C$0.12C$6,000.00
2/7/2017Gordon Edward ZelkoDirectorBuy50,000C$0.11C$5,500.00
1/31/2017Michael Bruno John Fr EnglandDirectorBuy20,000C$0.11C$2,200.00
(Data available from 1/1/2013 forward)


Trillium Therapeutics (TSE TRIL) News Headlines


SEC Filings

Trillium Therapeutics (TSE:TRIL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Trillium Therapeutics (TSE TRIL) Stock Chart for Friday, March, 23, 2018

Loading chart…

This page was last updated on 3/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.